Hancheng Cai

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Gas Chromatography Mass Spectrometry

Positron Emission Tomography

Ultra High Performance Liquid Chromatography

Top Venues

Journal of labelled compounds & radiopharmaceuticals

Molecular cancer therapeutics

Molecular pharmaceutics

This page only lists publications with an associated author ORCID identifier.

Publications

Kang-Po Li, Hancheng Cai
An Improved HPLC Separation Method for TSPO Radioligand [ 11 C]ER176 Clinical Production. Journal of labelled compounds & radiopharmaceuticals (2024)
Adam M Kase, Justyna Joanna Gleba, James L Miller, Erin Miller, Joachim L Petit, Michael T Barrett, Yumei Zhou, Ephraim E Parent, Hancheng Cai, Joshua A Knight, Jacob J Orme, Jordan P Reynolds, William F Durham, Thomas M Metz, Nathalie Meurice, Brandy Edenfield, Aylin A Demirer, Ahmet Bilgili, Peyton G Hickman, Matthew L Pawlush, Laura Marlow, Daniel P Wickland, Winston Tan, John A Copland Iii
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer. Molecular cancer therapeutics 23 (6) (2024)
Kang-Po Li, Hancheng Cai
An Improved HPLC Separation Method for TSPO Radioligand [ 11 C]ER176 Clinical Production. Journal of labelled compounds & radiopharmaceuticals 67 (7) (2024)
Adam M Kase, Justyna Joanna Gleba, James L Miller, Erin Miller, Joachim L Petit, Michael T Barrett, Yumei Zhou, Ephraim E Parent, Hancheng Cai, Joshua A Knight, Jacob J Orme, Jordan P Reynolds, William F Durham, Thomas M Metz, Nathalie Meurice, Brandy Edenfield, Aylin A Demirer, Ahmet Bilgili, Peyton G Hickman, Matthew L Pawlush, Laura Marlow, Daniel P Wickland, Winston Tan, John A Copland Iii
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer. Molecular cancer therapeutics 23 (6) (2024)
Ephraim E Parent, Justyna J Gleba, Joshua A Knight, Saad J Kenderian, John A Copland, Hancheng Cai
Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer. Molecular imaging and biology (2024)
Adam M Kase, Justyna Joanna Gleba, James L Miller, Erin Miller, Joachim L Petit, Michael T Barrett, Yumei Zhou, Ephraim E Parent, Hancheng Cai, Joshua A Knight, Jacob J Orme, Jordan P Reynolds, William F Durham, Thomas M Metz, Nathalie Meurice, Brandy Edenfield, Aylin A Demirer, Ahmet Bilgili, Peyton G Hickman, Matthew L Pawlush, Laura Marlow, Daniel P Wickland, Winston Tan, John A Copland Iii
Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer. Molecular cancer therapeutics (2024)
Kang-Po Li, Hancheng Cai
An Improved HPLC Separation Method for TSPO Radioligand [ 11 C]ER176 Clinical Production. Journal of labelled compounds & radiopharmaceuticals 67 (7) (2024)
Kang-Po Li, Justyna J Gleba, Ephraim E Parent, Joshua A Knight, John A Copland, Hancheng Cai
Radiosynthesis and Preliminary Evaluation of [ 11 C]SSI-4 for the Positron Emission Tomography Imaging of Stearoyl CoA Desaturase 1. Molecular pharmaceutics (2023)
Huailei Jiang, Yan Guo, Hancheng Cai, Nerissa Viola, Anthony Frank Shields, Otto Muzik, Csaba Juhasz
Automated radiosynthesis of 1-(2-[ 18 F]fluoroethyl)-L-tryptophan ([ 18 F]FETrp) for positron emission tomography (PET) imaging of cancer in humans. Journal of labelled compounds & radiopharmaceuticals (2023)
Huailei Jiang, Yan Guo, Hancheng Cai, Nerissa Viola, Anthony F Shields, Otto Muzik, Csaba Juhasz
Automated Radiosynthesis of 1-(2-[ 18 F]Fluoroethyl)-L-Tryptophan ([ 18 F]FETrp) for PET Imaging of Cancer in Humans. Journal of labelled compounds & radiopharmaceuticals (2023)
Adam M Kase, Winston Tan, John A Copland, Hancheng Cai, Ephraim E Parent, Ravi A Madan
The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer. Cancers 14 (6) (2022)